Nanobiotix Execs to Present at H.C. Wainwright Conference
Event summary
- Nanobiotix CEO Laurent Lévy and CFO Bart Van Rhijn to participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026.
- Event scheduled for 12:00 pm EDT / 6:00 pm CEST in New York, NY.
- Nanobiotix holds over 30 umbrella patents across three nanotechnology platforms.
- Company listed on Euronext Paris since 2012 and NASDAQ since December 2020.
The big picture
Nanobiotix's participation in the H.C. Wainwright conference underscores its push to engage with global investors as it navigates the complex landscape of late-stage biotech development. The company's focus on physics-based therapeutic approaches positions it uniquely in the oncology sector, but its ability to translate these innovations into commercial success will be critical. With a strong patent portfolio and dual listings on Euronext and NASDAQ, Nanobiotix is well-positioned to attract investment, but must demonstrate consistent progress in clinical trials to maintain momentum.
What we're watching
- Strategic Messaging
- How Nanobiotix positions its physics-based therapeutic approaches to differentiate itself in the competitive oncology space.
- Financial Health
- Whether the company can sustain its cash runway projections amid evolving market conditions.
- Regulatory Dynamics
- The pace at which Nanobiotix advances its late-stage clinical trials and secures regulatory approvals for its nanotechnology platforms.
Related topics